EZH2 and hepatocellular carcinoma: To further investigate the influence of EZH2 on FGFR4 inhibitor treatment in vivo, we generated zebrafish HCC primary tumors with liver-specific overexpression of EZH2 (KRASG12V+/EZH2+).